Skip to main content

Table 1 Characteristics of study participants at baseline and outcomes

From: Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study

 

Discovery cohort

Validation cohort

Control

Number

100

81

32

Age, years

69 (61, 75)*

72 (66, 79.5)*

61 (43, 67)

Male

86 (86)*

70 (86)*

18 (56)

Ever-smokers

91 (91)*

71 (88)*

8 (25)

%FVC

89.5 (73.7, 101.4)

79.5 (69.5, 89.2)

 

%DLCO

42.7 (35.2, 53.9)

45.1 (33.4, 57.1)

 

CPI

47.4 (37.3, 56.3)

  

PaO2, Torr (n = 96)

82.7 (76.4, 89.1)

81.7 (73.8, 88.6)

 

Six-minute walk distance, meter (n = 97)

463 (407, 520)

479.5 (421, 539)

 

Lowest SpO2 during the six-minute walk test, % (n = 97)

88 (82, 92)

89 (83, 91)

 

KL-6, IU/L

805 (607, 1260)

909 (595, 1600)

 

SP-D, ng/mL

236.5 (132.3, 348)

206.5 (121.6, 339.3)

 

LDH, IU/L

212 (193.8, 238.5)

223 (187.5, 249)

 

CPFE

30 (30)

  

Anti-fibrotic drug use at baseline

2 (2)

0 (0)

 

Anti-fibrotic drug use more than 6 months during the observational period

51 (51)

47 (58)

 

Mortality

52 (52)

19 (23)

 

Observation period, months

41 (19, 68)

19 (12, 27)

 
  1. Data are expressed as medians (interquartile ranges) or numbers (percentages)
  2. %FVC, the percentage of predicted forced vital capacity; %DLCO, the percentage of predicted diffusion capacity for carbon monoxide; CPI, composite physiologic index; PaO2, arterial pressure of oxygen; SpO2, percutaneous oxygen saturation; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D; LDH, lactate dehydrogenase; CPFE, combined pulmonary fibrosis and emphysema
  3. *P < 0.01 compared with controls (Mann–Whitney U test)